CJC-1295, Ipamorelin, MOTS-c, and Tesamorelin: How These Peptides Compare

All four peptides in this group touch metabolism, body composition, or growth hormone signaling, but only tesamorelin is FDA-approved for human use in the United States. CJC-1295 and ipamorelin are growth hormone secretagogues that are usually discussed as a pair, MOTS-c is a mitochondrial-derived peptide studied for metabolic effects, and tesamorelin is a GHRH analog approved to treat HIV-associated lipodystrophy. None of them is an approved treatment for general weight loss, anti-aging, or athletic performance.

Here is how each one works, how they stack up against each other, and what the actual research and community protocols look like.

What Each Peptide Does

Each compound has a different target, which is why they are not simply interchangeable.

• CJC-1295 is a growth hormone-releasing hormone (GHRH) analog. The version "with DAC" binds to albumin and stays active for days, while the version without DAC clears in roughly 30 minutes.
• Ipamorelin is a selective ghrelin receptor agonist. In the studies that measured it, it triggers a growth hormone pulse with relatively little effect on cortisol or prolactin.
• MOTS-c is a mitochondrial-derived peptide. Research centers on insulin sensitivity, glucose handling, and exercise-mimicking metabolic effects rather than growth hormone release.
• Tesamorelin is a GHRH analog sold as Egrifta. It is approved specifically for reducing excess abdominal visceral fat in people living with HIV and lipodystrophy.

CJC-1295, Ipamorelin, MOTS-c, and Tesamorelin Compared

For a direct cjc-1295 ipamorelin vs tesamorelin breakdown, the biggest practical differences are approval status, half-life, and what each peptide is actually studied for.

Peptide	Primary mechanism	FDA status	Main research focus	Typical route
CJC-1295 with DAC	GHRH analog, long half-life	Not approved	GH and IGF-1 elevation	Subcutaneous injection
CJC-1295 without DAC	GHRH analog, short half-life	Not approved	Paired with ghrelin mimetics	Subcutaneous injection
Ipamorelin	Selective ghrelin receptor agonist	Not approved	GH pulse quality and timing	Subcutaneous injection
Tesamorelin	GHRH analog	Approved (Egrifta)	Visceral fat reduction	Subcutaneous injection
MOTS-c	Mitochondrial-derived peptide	Not approved	Insulin sensitivity, metabolism	Investigational

The bottom line: tesamorelin is the only peptide here with a real regulatory approval and a defined patient population, while the other three are research chemicals with limited human data.

Can You Take CJC-1295 and Tesamorelin Together?

The question can you take cjc-1295 and tesamorelin together comes up often because both act on the same growth hormone axis. In theory, two GHRH analogs compete for the same receptor, so stacking them does not obviously add anything and may simply duplicate side effects.

Most community protocols instead pair a GHRH analog with a ghrelin mimetic, which is why CJC-1295 plus ipamorelin is far more common than CJC-1295 plus tesamorelin. That pairing combines two different signals rather than repeating one.

No controlled human trial has tested CJC-1295 and tesamorelin together in healthy adults, so any discussion of added benefit is speculation.

Stacking and Dosing in Community Protocols

The cjc 1295 ipamorelin tesamorelin stack shows up in bodybuilding forums as an all-purpose fat-loss and recovery combination, but the evidence for that specific trio is essentially nonexistent.

In forum discussions, cjc-1295 without dac and ipamorelin dosage is usually described as 100 mcg of each, injected subcutaneously once or twice daily, often before bed. Those numbers come from anecdotes, not from controlled trials.

Self-Reported Results vs. Published Data

Online reports describe better sleep, faster recovery, and gradual fat loss, and searches for cjc-1295 and ipamorelin reddit show how heavily anecdotal that information is. Self-reported outcomes are not evidence.

Published human data for CJC-1295 and ipamorelin is limited and short-term, generally measuring GH and IGF-1 blood levels rather than body composition in healthy adults.

Where MOTS-c Fits In

MOTS-c is not a growth hormone peptide at all, so it does not follow the same stacking logic as CJC-1295 or ipamorelin.

It was identified as a mitochondrial-derived peptide that can travel to the nucleus and influence gene expression related to metabolism. Animal studies show effects on insulin sensitivity, glucose tolerance, and fat oxidation.

Human data is very thin. MOTS-c is not FDA-approved, is not legally sold as a dietary supplement, and should not be treated as a replacement for exercise or prescribed metabolic care.

Safety, Legality, and Sourcing

Only tesamorelin has an FDA-approved product with a defined indication, dose, and monitoring plan. CJC-1295, ipamorelin, and MOTS-c are not approved for human use in the United States.

• Reported side effects of GHRH analogs and ghrelin mimetics include injection-site reactions, headache, flushing, and changes in blood sugar or appetite.
• Growth hormone axis peptides can raise IGF-1, and sustained elevation is a theoretical risk that clinicians monitor.
• The FDA has placed several of these peptides on its list of substances that cannot be compounded, which means most products sold online are unregulated.
• Purity and actual content in unregulated vials vary widely, and independent third-party testing is the exception rather than the rule.

Tesamorelin is the only peptide in this group with FDA approval, and that approval is limited to HIV-associated lipodystrophy.

Anyone considering these compounds should speak with a licensed healthcare professional first, particularly if they use insulin, have a personal or family history of cancer, or are pregnant or breastfeeding.

COMMON QUESTIONS

Frequently Asked Questions

Is tesamorelin the same as CJC-1295?

No. Both are GHRH analogs, but tesamorelin (Egrifta) is FDA-approved for reducing excess abdominal visceral fat in people with HIV-associated lipodystrophy, while CJC-1295 is not approved for any human use in the United States. They also differ in half-life and in the amount of human trial data available.

Can you stack CJC-1295 with ipamorelin and tesamorelin at the same time?

There is no clinical research supporting a three-peptide stack like this. CJC-1295 and tesamorelin both act on the GHRH receptor, so combining them does not clearly add benefit and may increase side effects. Most community protocols pair a GHRH analog with ipamorelin instead of using two GHRH analogs together.

Is MOTS-c a growth hormone peptide?

No. MOTS-c is a mitochondrial-derived peptide, and its research focus is on insulin sensitivity, glucose metabolism, and fat oxidation rather than growth hormone release. It is not FDA-approved and is not legally available as a dietary supplement in the United States.